Home / Reports

Reports

Use of biosimilars for chronic inflammatory diseases in Canada

The high cost of originator biologicals in Canada has created a demand for biosimilars as a way of reining in costs for Canadian public healthcare payers. However, although several biosimilars are now commercially available in the country for a variety of conditions [1]; it has been suggested that the uptake of biosimilars in Canada remains low [2].

Advantages and challenges of biosimilars approved in Europe and the US

Each biosimilar has its own unique challenges on the market. At the 2019 Generic + Biosimilar Medicines Conference, Dr Amy Gutierrez, Chief Pharmacy Officer of not-for-profit healthcare plan Kaiser Permanente outlined these factors for four blockbuster drugs: bevacizumab, filgrastim, rituximab and trastuzumab [1].

Proposed policies to maximize societal benefit of biosimilars

During the European Commission’s (EC) fifth workshop on biosimilars, which was held in Brussels, Belgium on 30 October 2019, the subject of what policies might maximize the benefit of biosimilars to societies across Europe was discussed [1].

Optimizing the benefits of biosimilars for society

How to optimize the benefits of biosimilars for society was a topic discussed during the European Commission’s (EC) fifth workshop on biosimilars, which was held in Brussels, Belgium on 30 October 2019 [1].

Japanese opportunity for biosimilars

Japan is proving to be a favourable market for biosimilars, with more than half a billion dollars worth in sales waiting for prospective makers of biosimilars.

Brand-name discount cards increase private insurance spending in Canada

The use of brand-name discount cards, designed to help patients save money, increase private insurance expenditure by almost 50%, finds a study published in the Canadian Medical Association Journal [1].

EC workshop on biosimilars focusses on sustainability

The European Commission (EC) held its fifth workshop on biosimilars in Brussels, Belgium on 30 October 2019. The focus of this workshop was the sustainability of the biosimilar medicines sector [1].

How to support a viable US biosimilars market

In a previous article Ms Juliana Reed, President of the Biosimilars Forum, outlined why the US biosimilars market is sluggish at the DIA Biosimilars Conference, which was held on 23‒24 September 2019 in Bethesda, Maryland, USA [1].

The sluggish US biosimilars market

Juliana Reed, President of the Biosimilars Forum, gave a presentation on ‘The State of the Biosimilars Market’ at the Drug Information Association’s (DIA) Biosimilars Conference, which was held on 23-24 September 2019 in Bethesda, Maryland, USA [1].

Varied approach to interchangeability across the MENA region

To achieve global agreement on issues of regulatory approval of biosimilars, open discussion across national borders and between different stakeholder groups is key. A lack of agreement between countries that make up the Middle East and North Africa (MENA) region, particularly in the area of interchangeability and switching, was made clear at a meeting organized by the Generics and Biosimilars Initiative (GaBI).